15 paragraphs in Risk Factors of the 10-K filed Feb 27, 2026
with nothing like them in the 10-K filed Feb 28, 2025. Quoted exactly.
Paragraphs that were only edited are under 10-K change.
Compared with the Risk Factors in the latest 10-K of the other 59 Health care companies:
a paragraph with at least half its words the same at another company is called similar, and the companies are listed under it.
A paragraph most of them have is marked boilerplate. No line means no other company has one like it.
This counts text; it does not say how serious a risk is.
•Solventum has and will continue to incur costs in connection with the separation from 3M and the related transition agreements entered into with 3M.
Read in the 10-K ↗
services may also be more expensive than the amounts reflected in its historical consolidated financial statements or less efficient than the systems and services 3M is expected to provide during the transition period to Solventum.
Read in the 10-K ↗
The deployment and use of artificial intelligence ("AI"), machine learning, or other emerging technologies in Solventum’s products and services, including as part of its research and development efforts, or its failure to adapt its products or services to industry trends and developments related to such technologies in a timely manner, or at all, could adversely affect Solventum’s business, financial condition, results of operations and cash flows.
Similar paragraph at 1 of 59 other Health care companies:
BDXSolventum has begun to deploy AI in its products and services, including as part of its research and development efforts, and Solventum expects to continue to explore additional uses as AI continues to develop. In addition, Solventum intends to devote significant resources to develop and deploy cloud, edge and software solutions in its healthcare solutions. For example, Solventum has incorporated AI into certain products in the Health Information Systems business segment and certain of its digital offerings and expects to continue to build AI into additional products. Any disruption or failure in the AI, machine learning, or other emerging technologies Solventum deploys or uses in its products and services, including as part of its research and development efforts, could adversely impact Solventum’s business, including as a result of flawed AI algorithms, insufficient or biased datasets, malfunctions or manipulations, unintentional release of confidential information, or product or service delays or recalls. In addition, any failure to successfully deploy or use such technologies in Solventum’s products and services, or to adapt to medical technology industry trends and developments related to such technologies in a timely manner (or at all), particularly as competitors incorporate such technologies into new and existing products and services, could adversely affect customer demand for Solventum’s products and its competitiveness. The deployment of AI, machine learning or other emerging technologies into Solventum’s products and services will require additional investment and increase its costs. Furthermore, the rapid advancement of technology, including AI, creates additional risks as Solventum includes such technology into its products and services, including from confidentiality, privacy, data protection, cybersecurity and compliance perspectives, and raises intellectual property issues and operational, technological and other concerns. Any of the above factors could adversely affect Solventum’s business, financial condition, results of operations and cash flows.
Read in the 10-K ↗
Our reputation and our brands could in the future be damaged by negative publicity, whether or not valid. Negative publicity could relate to our company, our brands, our products, our supply chain, our ingredients, our packaging, our sustainability and social impact practices, our employees or any other aspect of our business. Our reputation or our brands could
Read in the 10-K ↗
Solventum may not be able to effectively integrate acquired businesses into its operations or achieve expected cost savings or profitability from its acquisitions.
Similar paragraph at 1 of 59 other Health care companies:
ZBH•unforeseen difficulties in integrating personnel and sales forces, operations, manufacturing, logistics, research and development, information technology, compliance, vendor management, communications, purchasing, accounting, marketing, administration and other systems and processes;
Similar paragraph at 1 of 59 other Health care companies:
ZBH•unforeseen difficulties related to entering markets for which or geographic regions where Solventum does not have prior experience;
Similar paragraph at 1 of 59 other Health care companies:
ZBH•unforeseen risks and liabilities associated with businesses acquired, including any unknown vulnerabilities in acquired technology, compromises of acquired data or noncompliance with data privacy requirements; and/or
Similar paragraph at 1 of 59 other Health care companies:
ZBH•inability to generate sufficient revenue or realize sufficient cost savings to offset acquisition or investment costs.
Similar paragraph at 1 of 59 other Health care companies:
ZBHAs a result, if Solventum fails to evaluate and execute acquisitions properly, Solventum might not achieve the anticipated benefits of such acquisitions, and Solventum may incur costs in excess of what it anticipates. These risks would likely be greater in the case of larger acquisitions.
Similar paragraph at 1 of 59 other Health care companies:
ZBHSolventum’s restructuring program may not be successful or Solventum may not fully realize the expected cost savings and/or operating efficiencies from its restructuring initiatives.
Similar paragraph at 1 of 59 other Health care companies:
ZBHSolventum has initiated a multiyear restructuring program, 'Transform for the Future', which is designed to further enable its long-term growth strategy and ensure it's best positioned to compete-to-win in a rapidly changing healthcare environment. Designed to transform the cost structure, enhance operational efficiency, and reposition for profitable growth, the primary activities of the restructuring program include operating structure optimization and workforce reorganization, procurement and cost management, supply chain, manufacturing and global footprint optimization, and streamlining systems and increased automation to improve operational efficiency. Additionally, as a result of the restructuring initiative, Solventum may experience a loss of continuity, loss of accumulated knowledge and/or inefficiencies during transitional periods. The restructuring initiative presents risks that may impair Solventum’s ability to achieve anticipated operating enhancements and/or cost reductions, or otherwise harm its business, including higher than anticipated costs in implementing the restructuring program, as well as management distraction. For more information on Solventum’s restructuring program, see Note 14 to Solventum’s consolidated financial statements. If Solventum fails to achieve some or all of the expected benefits of its restructuring program, or if costs related to the restructuring program are more than anticipated, it could have a material adverse effect on Solventum’s competitive position, business, financial condition, results of operations and cash flows.
Similar paragraph at 1 of 59 other Health care companies:
ZBH
Solventum operates globally, including in some jurisdictions that pose potentially elevated risks of fraud or corruption or increased risk of internal control issues, and is subject to risks related to international, federal, state and local treaties, laws and
Read in the 10-K ↗
with these laws and regulations could subject Solventum or its officers and employees to criminal and civil financial penalties.
Read in the 10-K ↗
New in the latest 10-Q
21 paragraphs in the 10-Q filed Nov 5, 2026 with nothing like
them in the 10-Q filed Aug 5, 2026 (at least half the words must differ; new numbers alone do not count).
Quoted exactly, grouped by the item heading above them. This is text that changed, not a judgement of how serious it is.
Financial statements and notes
The Company completed the sale of the Purification and Filtration business in the third quarter of 2025. This resulted in a net gain of $1.5 billion for both the third quarter and first nine months of 2025.
Read in the 10-Q ↗
Loss on debt extinguishment, net includes charges incurred in the third quarter of 2025 from the differential between carrying value and the amount paid to acquire the tendered Senior Notes and related expenses. These charges were partially offset by the gain from interest rate swaps entered into and subsequently settled in connection with the sale of the Purification and Filtration business.
Read in the 10-Q ↗
In the first nine months of 2026, cash flows used in financing activities decreased as compared to the first nine months of 2025, primarily due to the Company's repayment of $1.9 billion of senior notes via tender offers upon completion of the sale of the Purification and Filtration business and $770 million repayment of outstanding principal issued under the senior term loan credit facility in the third quarter of 2025. Activity for the first nine months of 2026 primarily relates to the Company's share repurchase program that commenced during the year.
Read in the 10-Q ↗
• inability to successfully deploy our new ERP system and any disruption to our business as a result of such deployment;
Read in the 10-Q ↗
Risk Factors
identification or implementation of a strategic alternative, and any alternative that is pursued may not be completed within
Read in the 10-Q ↗
any given timeframe or at all. We may be unable to successfully execute any strategic alternative or realize any or all
Read in the 10-Q ↗
strategic, operational, or financial benefits. The review process may also create uncertainty to our customers, employees
Read in the 10-Q ↗
and other constituencies or counterparties and divert management attention from ongoing operations. We may incur costs
Read in the 10-Q ↗
and expenses in connection with the review process, whether or not a transaction is successful. In addition, we may
Read in the 10-Q ↗
determine to abandon the review, pursue a different structure, or take no action. Any of these factors could have a material
Read in the 10-Q ↗
adverse effect on our business, financial condition, results of operations, or cash flows.
Read in the 10-Q ↗
Other information
The Company’s definitive proxy statement for the 2026 annual meeting of shareholders of the Company, which was filed with the SEC on March 27, 2026, contained typographical errors in the section entitled “Questions & Answers About The Annual Meeting - What do I need to know to submit proposals and what are the deadlines to propose actions for consideration or to nominate individuals to serve as directors at the 2027 annual meeting of shareholders?” concerning the deadline for shareholders to bring nominations for directors or a proposal that a shareholder intends to present, but does not intend to have included in the Company's proxy statement and form of proxy at the Company’s 2027 annual meeting of shareholders. The corrected deadline is February 12, 2027, as set forth below.
Read in the 10-Q ↗
Requirements for Director Nominees to Be Considered for Inclusion in our Proxy Materials (“Proxy Access”).
Read in the 10-Q ↗
•Pursuant and subject to the proxy access provisions in our Bylaws, a shareholder or group of up to twenty shareholders, owning three percent or more of our outstanding common stock continuously for at least three years may nominate and include in our proxy materials director nominees constituting up to the greater of two directors or twenty percent of the number of directors then in office. Shareholder requests to include director nominees in our proxy statement and form of proxy relating to the 2027 annual meeting of shareholders must be delivered to our Corporate Secretary not earlier than January 15, 2027 and not later than the close of business on February 12, 2027.
Read in the 10-Q ↗
•In addition, the notice must set forth the information required by our Bylaws with respect to each director nomination that a shareholder requests for inclusion in our proxy materials.
Read in the 10-Q ↗
•Notice Requirements for Other Director Nominees or Shareholder Proposals to Be Brought Before the 2027 Annual Meeting of Shareholders.
Read in the 10-Q ↗
•Notice of any director nomination or a proposal that a shareholder intends to present at the 2027 annual meeting of shareholders, but does not intend to have included in our proxy statement and form of proxy relating to the 2027 annual meeting of shareholders, must be delivered to our Corporate Secretary not earlier than the close of business on January 15, 2027 and not later than the close of business on February 12, 2027.
Read in the 10-Q ↗
•In addition, the notice must set forth the information required by our Bylaws with respect to each director nomination or other proposal.
Read in the 10-Q ↗
Item 6
(10.1) Amendment No. One, dated October 26, 2026 to the Master Supply Agreement by and between Solventum Corporation, a Delaware corporation and 3M Company, a Delaware Corporation (filed herewith).
Read in the 10-Q ↗
(10.2) Amendment No. One, dated October 26, 2026, to the Reverse Master Supply Agreement by and between Solventum Corporation, a Delaware corporation and 3M Company, a Delaware Corporation (filed herewith).
Read in the 10-Q ↗
(104) Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)
Read in the 10-Q ↗
The 10-Q's risk factors against the 10-K
Item 1A of the 10-Q filed Nov 5, 2026 against Item 1A of the 10-K filed Feb 27, 2026.
A 10-Q repeats only the risks that changed, so a 10-K paragraph that is missing from it is not counted as removed.
Added is a paragraph with nothing like it in the 10-K, Reworded a sentence that is in both with several words changed,
Quiet changes a sentence in both where one to four words changed and one is a hedge or a modal
(cut words struck through, new words highlighted and underlined).
Text on the page, not a score; each links to the filing at sec.gov.
Added10-Q 2026-11-05 vs 10-K 2026-02-27
Our business, financial condition and operating results are affected by a number of factors, whether currently known or unknown, including risks specific to us or our industry, as well as risks that affect businesses in general. In addition to the factors set forth under the caption "Cautionary Note Concerning Forward-Looking Statements" set forth in this Quarterly Report on Form 10-Q, you should carefully consider the risk factors described in Part I, Item 1A of our Annual Report on Form 10-K for the fiscal year ended December 31, 2025 and the risk factor set forth below, which updates, and should be read in conjunction with, the risk factors disclosed in such Annual Report on Form 10-K. Other than the risk factor set forth below, we believe there have been no material changes from the risk factors disclosed in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025. However, additional risks and uncertainties not currently known or which we currently deem to be immaterial may also materially adversely affect our business, financial condition, or results of operations.
Read it in the 10-Q at sec.gov ↗
Added10-Q 2026-11-05 vs 10-K 2026-02-27
Discussion of these factors is incorporated by reference into and considered an integral part of Part I, Item 2, “Management’s Discussion and Analysis of Financial Condition and Results of Operations.”
Read it in the 10-Q at sec.gov ↗
Added10-Q 2026-11-05 vs 10-K 2026-02-27
Risks related to Solventum's review of strategic alternatives for its health information system business
Read it in the 10-Q at sec.gov ↗
Added10-Q 2026-11-05 vs 10-K 2026-02-27
We are evaluating strategic alternatives for our health information systems business. The review may not result in the
Read it in the 10-Q at sec.gov ↗
Added10-Q 2026-11-05 vs 10-K 2026-02-27
identification or implementation of a strategic alternative, and any alternative that is pursued may not be completed within
Read it in the 10-Q at sec.gov ↗
Added10-Q 2026-11-05 vs 10-K 2026-02-27
any given timeframe or at all. We may be unable to successfully execute any strategic alternative or realize any or all
Read it in the 10-Q at sec.gov ↗
Added10-Q 2026-11-05 vs 10-K 2026-02-27
strategic, operational, or financial benefits. The review process may also create uncertainty to our customers, employees
Read it in the 10-Q at sec.gov ↗
Added10-Q 2026-11-05 vs 10-K 2026-02-27
and other constituencies or counterparties and divert management attention from ongoing operations. We may incur costs
Read it in the 10-Q at sec.gov ↗
Added10-Q 2026-11-05 vs 10-K 2026-02-27
and expenses in connection with the review process, whether or not a transaction is successful. In addition, we may
Read it in the 10-Q at sec.gov ↗
Added10-Q 2026-11-05 vs 10-K 2026-02-27
determine to abandon the review, pursue a different structure, or take no action. Any of these factors could have a material
Read it in the 10-Q at sec.gov ↗
Added10-Q 2026-11-05 vs 10-K 2026-02-27
adverse effect on our business, financial condition, results of operations, or cash flows.
Read it in the 10-Q at sec.gov ↗
